Annual EBITDA
-$66.57 M
-$34.27 M-106.13%
31 December 2023
Summary:
Acrivon Therapeutics Common Stock annual earnings before interest, taxes, depreciation & amortization is currently -$66.57 million, with the most recent change of -$34.27 million (-106.13%) on 31 December 2023. During the last 3 years, it has fallen by -$63.41 million (-2009.89%). ACRV annual EBITDA is now -2009.89% below its all-time high of -$3.15 million, reached on 01 December 2020.ACRV EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
-$24.89 M
-$3.68 M-17.35%
30 September 2024
Summary:
Acrivon Therapeutics Common Stock quarterly earnings before interest, taxes, depreciation & amortization is currently -$24.89 million, with the most recent change of -$3.68 million (-17.35%) on 30 September 2024. Over the past year, it has dropped by -$8.88 million (-55.52%). ACRV quarterly EBITDA is now -834.97% below its all-time high of -$2.66 million, reached on 01 September 2021.ACRV Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
-$84.45 M
-$8.88 M-11.76%
30 September 2024
Summary:
Acrivon Therapeutics Common Stock TTM earnings before interest, taxes, depreciation & amortization is currently -$84.45 million, with the most recent change of -$8.88 million (-11.76%) on 30 September 2024. Over the past year, it has dropped by -$28.96 million (-52.20%). ACRV TTM EBITDA is now -3072.28% below its all-time high of -$2.66 million, reached on 01 September 2021.ACRV TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ACRV EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -106.1% | -55.5% | -52.2% |
| 3 y3 years | -2009.9% | -484.7% | -1120.5% |
| 5 y5 years | - | - | - |
ACRV EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -2009.9% | at low | -484.7% | at low | -1120.5% | at low |
| 5 y | 5 years | -2009.9% | at low | -835.0% | at low | -3072.3% | at low |
| alltime | all time | -2009.9% | at low | -835.0% | at low | -3072.3% | at low |
Acrivon Therapeutics Common Stock EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$24.89 M(+17.4%) | -$84.45 M(+11.8%) |
| June 2024 | - | -$21.21 M(+21.6%) | -$75.56 M(+8.3%) |
| Mar 2024 | - | -$17.44 M(-16.6%) | -$69.74 M(+4.8%) |
| Dec 2023 | -$66.57 M(+106.1%) | -$20.90 M(+30.6%) | -$66.57 M(+20.0%) |
| Sept 2023 | - | -$16.00 M(+4.0%) | -$55.48 M(+13.4%) |
| June 2023 | - | -$15.39 M(+7.9%) | -$48.94 M(+24.2%) |
| Mar 2023 | - | -$14.27 M(+45.3%) | -$39.39 M(+22.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2022 | -$32.29 M(+100.0%) | -$9.82 M(+3.8%) | -$32.29 M(+20.8%) |
| Sept 2022 | - | -$9.46 M(+61.8%) | -$26.73 M(+34.1%) |
| June 2022 | - | -$5.85 M(-18.4%) | -$19.93 M(+41.5%) |
| Mar 2022 | - | -$7.17 M(+68.4%) | -$14.09 M(+103.6%) |
| Dec 2021 | -$16.15 M(+411.8%) | - | - |
| Dec 2021 | - | -$4.26 M(+59.9%) | -$6.92 M(+159.9%) |
| Sept 2021 | - | -$2.66 M | -$2.66 M |
| Dec 2020 | -$3.15 M | - | - |
FAQ
- What is Acrivon Therapeutics Common Stock annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for Acrivon Therapeutics Common Stock?
- What is Acrivon Therapeutics Common Stock annual EBITDA year-on-year change?
- What is Acrivon Therapeutics Common Stock quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for Acrivon Therapeutics Common Stock?
- What is Acrivon Therapeutics Common Stock quarterly EBITDA year-on-year change?
- What is Acrivon Therapeutics Common Stock TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for Acrivon Therapeutics Common Stock?
- What is Acrivon Therapeutics Common Stock TTM EBITDA year-on-year change?
What is Acrivon Therapeutics Common Stock annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of ACRV is -$66.57 M
What is the all time high annual EBITDA for Acrivon Therapeutics Common Stock?
Acrivon Therapeutics Common Stock all-time high annual earnings before interest, taxes, depreciation & amortization is -$3.15 M
What is Acrivon Therapeutics Common Stock annual EBITDA year-on-year change?
Over the past year, ACRV annual earnings before interest, taxes, depreciation & amortization has changed by -$34.27 M (-106.13%)
What is Acrivon Therapeutics Common Stock quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of ACRV is -$24.89 M
What is the all time high quarterly EBITDA for Acrivon Therapeutics Common Stock?
Acrivon Therapeutics Common Stock all-time high quarterly earnings before interest, taxes, depreciation & amortization is -$2.66 M
What is Acrivon Therapeutics Common Stock quarterly EBITDA year-on-year change?
Over the past year, ACRV quarterly earnings before interest, taxes, depreciation & amortization has changed by -$8.88 M (-55.52%)
What is Acrivon Therapeutics Common Stock TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of ACRV is -$84.45 M
What is the all time high TTM EBITDA for Acrivon Therapeutics Common Stock?
Acrivon Therapeutics Common Stock all-time high TTM earnings before interest, taxes, depreciation & amortization is -$2.66 M
What is Acrivon Therapeutics Common Stock TTM EBITDA year-on-year change?
Over the past year, ACRV TTM earnings before interest, taxes, depreciation & amortization has changed by -$28.96 M (-52.20%)